In this study, we investigated the role of CD24 as a therapeutic target preclinically using cell lines and primary patient-derived samples, with a particular focus on MCL and DLBCL, but also other B-cell lymphomas such as follicular lymphoma and Burkitt lymphoma. Here, CD24 is linked to follicular lymphoma.